Commencez
ReutersReuters

Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder

RefinitivMoins d'1 minute de lecture
CYBN

Cybin Inc CYBN:

  • CYBIN ANNOUNCES ADDITIONAL U.S. PATENT SUPPORTING ITS CYB003 BREAKTHROUGH THERAPY PROGRAM IN PHASE 3 DEVELOPMENT FOR MAJOR DEPRESSIVE DISORDER

Actions américainesActions canadiennesReuters
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Connectez-vous ou créez un compte gratuit à vie pour lire ces nouvelles

Plus de nouvelles provenant de Reuters